Additional BIO-Europe 2009 Profiles

VIENNA--(BUSINESS WIRE)--BIO-Europe 2009 takes place November 2-4, 2009 at the Messe Wien Exhibition & Congress Center in Vienna.

BIO-Europe 2009 breaking news releases, advisories, photos, and multimedia are available at Tradeshownews.com, Business Wire's trade show, conference, and event news resource.

Business Wire is the official news wire services for BIO-Europe 2009. Listed below are additional BIO-Europe 2009 profiles.

Company:	BAC BV
Media Contact:	Kathryn Robertson
Phone:	44 (0)1260 296 506
E-mail:	[e-mail]
Web:	www.bac.nl
BAC provides the biopharmaceutical industry with unparalleled protein purification technology for drug manufacture and research. The Company produces affinity ligands that enable the rapid, reliable, and robust purification of any target molecule - a platform technology that can fit into existing downstream processes.
BAC markets its ligands for large-scale processes and also supplies smaller scale research products. BAC ligands are currently incorporated into a number of customer processes in various phases of clinical development and scale-up. BAC launched 5 products in 2009 and has an extensive product pipeline that includes ligands for blood factors, antibodies, biosimilars, vaccine components and viruses.
Company:	BioM Biotech Cluster Development GmbH
Stand:	65
Media Contact:	Dr. Georg Kääb
Phone:	49-89-899679-19
E-mail:	[e-mail]
Web:	www.bio-m.org
BioM Biotech Cluster Development GmbH serves as the coordinating agency of the Munich Biotech Cluster, and is the top address for all biotechnology companies and startups in the region. The Munich Biotech Cluster is a constantly growing hotbed of innovation. The Greater Munich Area counts over 20.000. persons employed by more than 350 companies in the life science sector (Biotech, Pharma, CRO, Suppliers) making Munich one of the top regions all over Europe. BioM provides support in marketing, communications, and public promotion, also maintaining an information portal at www.bio-m.org. The web site offers an extensive company-database, news updates and a job forum. In addition to business advice BioM offers a wide range of seminars and events to biotech entrepreneurs and their employees. BioM supports the BIO-Europe 2010 in Munich.
Company:	BLIRT
Media Contact:	Adam Gosiewski
Phone:	48 587396150
E-mail:	[e-mail]
Web:	www.blirt.eu
BLIRT (BioLab Innovative Research Technologies) is a privately held research-based company. We search for innovative solutions in the fields of medicine, pharmaceuticals and industrial biotechnology. We are characterized by our strong research capability, resulting from modern technical facilities and a qualified and experienced research team. To ensure top quality research, BLIRT works in close collaboration with Polish and foreign scientists representing a number of disciplines including microbiology, biotechnology, organic chemistry and medicine.
BLIRT'S AREAS OF ACTIVITY INCLUDE:
BLIRT ENZYMES
Research services
Our own research projects
Collection of new enzymes
BLIRT R&D SERVICE PLATFORM
BLIRT (DNA GDANSK) PRODUCTS
MOLECULLAR DIAGNOSTIC LAB
Company:	CMC Biologics
Stand:	95
Media Contact:	Gitte Jørgensen
Phone:	45 7020 9470
E-mail:	[e-mail]
Web:	www.cmcbio.com
CMC Biologics (CMC) is a Contract Manufacturing Organization (CMO) with biomanufacturing facilities in Europe and the USA. The company delivers a wide range of integrated solutions encompassing both mammalian cell culture and microbial fermentation technologies. Some of our solutions include:
•Cell line design and construction, bioprocess development and biomanufactruing scale-up
•cGMP Production of biopharmaceuticals for: preclinical, clinical trial phase I,II,III, and market supply
•Analytical and Formulation development
•cGMP stability testing
•CMC regulatory life-cycle management
•New technology evaluation
The company also offers non-exclusive license to the proprietary CHEF1 expression system for rapid generation of stable cell lines and production in mammalian cell culture.
Company:	Glycotope GmbH
Media Contact:	Georg Adelberger
Phone:	49-30-9489-2604
E-mail:	[e-mail]
Web:	www.glycotope.com
Glycotope is a leading innovator in glycomics and immunotherapeutics. It has developed novel therapeutic antibodies and platform technologies to optimize the glycosylation of new biological entities. Glycotope´s pipeline consists of both novel and improved glycooptimized antibodies and a glycooptimized hormone. They have been developed in GlycoExpressTM, Glycotope´s proprietary toolbox of human cell-lines for screening, development and production of glycooptimized biopharmaceuticals.
The recent approval of the cancer-targeting antibody GT-MAB 2.5-GEXTM for clinical phase I also represents a key milestone in the development of GlycoExpressTM, that simultaneously has gained approval for development & production of biotherapeutics to be administered in clinical settings.
Company:	Hikma Pharmaceuticals PLC
Ticker Symbol & Exchange:	HIK
Media Contact:	Osama Nabulsi
Phone:	962 (6580) 2960 ext 2016
E-mail:	[e-mail]
Web:	www.hikma.com
With a sales and marketing team of over 1,400 people across MENA, Hikma is the local marketing partner of choice for companies looking to access this fast growing market. This conference will give us the opportunity to explore licensing and partnership opportunities with a range of global pharmaceutical and biotechnology companies.
Inquiries:
Hikma Pharmaceuticals PLC
Susan Ringdal, Investor Relations Director Tel: [phone]
Company:	Immunovaccine Inc.
Ticker Symbol & Exchange:	TSX-Venture: IMV
Media Contact:	Jennifer Ayotte
Phone:	902-492-1819
E-mail:	[e-mail]
Web:	www.imvaccine.com
Immunovaccine Inc (TSX-V:IMV) is a vaccine development company focused on the commercialization of its novel vaccine technology and product candidates. The company continues to strengthen its vaccine pipeline through licensing and strategic partnerships to develop therapeutic cancer and infectious disease vaccines. www.imvaccine.com
Company:	Izun Pharmaceuticals
Media Contact:	Dr. Scott Lawrence
Phone:	972-54-727-0189
E-mail:	[e-mail]
Web:	www.izunpharma.com
Izun Pharmaceutical recently completed breakthrough trial in the treatment of Gingivitis. PerioRinse is a dual effect mouth rinse that combines a powerful anti-inflammatory with an anti-bacterial. In a 90 patient trial, Izun demonstrated that PerioRinse is more effective than the leading mouth rinses in treating Gingivitis.
The trial is based upon a 90 patient experimental gingivitis model. PerioRinse was compared to leading mouthwashes in a head to head trial, and demonstrated significantly superior benefit. This data supports the results of previous trials that
Izun specializes in developing anti inflammatory drugs and whose model is based upon licensing products to Pharma & consumer care companies for commercialization.
Company:	Sochinaz / Bachem
Web:	www.sochinaz.com
Sochinaz, a Swiss chemical company and a member of the Bachem group, is specialized in API manufacturing. We collaborate with biotech and pharma companies worldwide since almost 40 years. Our state-of-the-art facilities meet full cGMP compliance. Moreover, our support includes all CMC and regulatory services.
Sochinaz brings production projects successfully from laboratory to commercial scale. Highly-potent active ingredients are produced in a dedicated facility (class 4, OEL < 0.1µg/m3/8h), either small molecules or conjugates with peptides.

About Business Wire

Business Wire, a Berkshire Hathaway company, is utilized by tens of thousands of member companies and organizations worldwide to functionally enhance and communicate investor relations and public relations content to target audiences. As a recognized disclosure service in the United States, Canada and a dozen European countries, Business Wire facilitates the simultaneous flow of market-moving press releases from corporations to financial markets and their audiences, including regulatory authorities, media, investors, financial information systems and consumer news services. Business Wire also handles XBRL tagging, document formatting and regulatory filing into EDGAR, SEDAR, FSA and other systems.

Communications professionals turn to Business Wire to optimize and issue press releases, photos and multimedia to news organizations, journalists, trade publications, search engines, and individuals, with full-text posting to web sites, online services and databases. A range of distribution options enables members to target by geography, industry, news theme and audience demographics.

Founded in 1961, Business Wire has dual headquarters in San Francisco and New York, with 30 bureaus in cities including Los Angeles, Chicago, Boston, Miami, Paris, Frankfurt, London, Brussels, Tokyo, Toronto and Sydney and reciprocal offices throughout the world. Business Wire's patented NX data platform supports XML, XHTML and XBRL code that enhances news release interactivity, social media sharing and search engine optimization. More information about Business Wire and its services is located on its website at www.BusinessWire.com.